Home > Insider Trading > Filing (0001415889-24-018708)

Filing Details

Accession Number:: 0001415889-24-018708
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-07-01 21:29:04
Reporting Period:: 2024-06-27

Accepted Time:: 2024-07-01 21:29:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1768446	Eliem Therapeutics Inc.	ELYM	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1346824	Ra Capital Management, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	No	No
1384859	Peter Kolchinsky	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1619841	M. Rajeev Shah	C/O Ra Capital Management, L.p. 200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1780117	Ra Capital Nexus Fund, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1825376	Ra Capital Nexus Fund Ii, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No
1883840	Ra Capital Nexus Fund Iii, L.p.	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-06-27	973,000	$0.00	11,572,586	No	4	A	Indirect	See footnotes
Common Stock	Acquisiton	2024-06-27	2,479,872	$0.00	2,479,872	No	4	A	Indirect	See footnotes
Common Stock	Acquisiton	2024-06-27	1,807,000	$0.00	1,807,000	No	4	A	Indirect	See footnotes
Common Stock	Acquisiton	2024-06-27	11,949,171	$3.84	23,521,757	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2024-06-27	1,059,375	$3.84	2,866,375	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Indirect	See footnotes
No	4	A	Indirect	See footnotes
No	4	A	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,226,497	Indirect	See footnotes
Common Stock	483,679	Indirect	See footnotes
Common Stock	841,087	Indirect	See footnotes

Footnotes

Received in exchange for equity of Tenet Medicines, Inc. ("Tenet") pursuant to an Agreement and Plan of Merger and Reorganization, dated April 10, 2024, by and among the Issuer, Tango Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Tango Merger Sub") and Tenet (the "Acquisition Agreement"). Under the terms of the Acquisition Agreement, on June 27, 2024, Tenet was acquired by the Issuer through the merged of Tango Merger Sub with and into Tenet (the "Acquisition"), with Tenet surviving the Acquisition as a wholly-owned subsidiary of the Issuer.
These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
These securities are held directly by Sera.
These securities are held directly by Nexus Fund III.
These securities are held directly by the Nexus Fund.
These securities are held directly by the Nexus Fund II.
These securities are held directly by the Account.